The Antibiotic Arms Race: Current and Emerging Therapy for Klebsiella pneumoniae Carbapenemase (KPC) - Producing Bacteria.

This article encompasses both the past and present treatment options for the management of KPC-producing bacterial infections via an extensive review and critical appraisal of the current literature. Expert opinion: Traditional treatment options can no longer be recommended as first-line options for the management of KPC-producing bloodstream infections (BSIs). Ceftazidime-avibactam or meropenem-vaborbactam plus or minus an aminoglycoside or polymyxin should be utilized as backbone therapies given their superior efficacy and safety profiles when compared to traditional treatment options. For susceptible KPC-producing urinary tract infections, it is reasonable to consider treatment with an aminoglycoside or with fosfomycin as a monotherapy. All of these decisions should be based on patient specific characteristics, severity of infection and source control, susceptibility patterns, and input from infectious diseases experts. PMID: 30346216 [PubMed - as supplied by publisher]
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research